Crossmark

First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

Crossref DOI link: https://doi.org/10.1245/s10434-018-6807-9

Published Online: 2018-10-15

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gulhati, Pat

Prakash, Laura

Katz, Matthew H. G.

Wang, Xuemei

Javle, Milind

Shroff, Rachna

Fogelman, David

Lee, Jeffrey E.

Tzeng, Ching-Wei D.

Lee, Jeffrey H.

Weston, Brian

Tamm, Eric

Bhosale, Priya

Koay, Eugene J.

Maitra, Anirban

Wang, Huamin

Wolff, Robert A.

Varadhachary, Gauri R.
License Information

Text and Data Mining valid from 2018-10-15
More Information

Article History

Received: 13 May 2018

First Online: 15 October 2018

Disclosure

: Gauri R. Varadhachary serves on the strategic council and scientific advisory board and received an honorarium from Celgene. The remaining authors have no conflicts of interest.